vs

Side-by-side financial comparison of Bristol Myers Squibb (BMY) and Oracle Corporation (ORCL). Click either name above to swap in a different company.

Oracle Corporation is the larger business by last-quarter revenue ($16.1B vs $11.5B, roughly 1.4× Bristol Myers Squibb). Oracle Corporation runs the higher net margin — 38.2% vs 23.3%, a 14.9% gap on every dollar of revenue. On growth, Oracle Corporation posted the faster year-over-year revenue change (14.2% vs 11.0%). Over the past eight quarters, Oracle Corporation's revenue compounded faster (10.0% CAGR vs -3.0%).

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid art...

An oracle is a person or thing considered to provide insight, wise counsel or prophetic predictions, most notably including precognition of the future, inspired by deities. If done through occultic means, it is a form of divination.

BMY vs ORCL — Head-to-Head

Bigger by revenue
ORCL
ORCL
1.4× larger
ORCL
$16.1B
$11.5B
BMY
Growing faster (revenue YoY)
ORCL
ORCL
+3.2% gap
ORCL
14.2%
11.0%
BMY
Higher net margin
ORCL
ORCL
14.9% more per $
ORCL
38.2%
23.3%
BMY
Faster 2-yr revenue CAGR
ORCL
ORCL
Annualised
ORCL
10.0%
-3.0%
BMY

Income Statement — Q1 FY2026 vs Q2 FY2026

Metric
BMY
BMY
ORCL
ORCL
Revenue
$11.5B
$16.1B
Net Profit
$2.7B
$6.1B
Gross Margin
Operating Margin
29.5%
Net Margin
23.3%
38.2%
Revenue YoY
11.0%
14.2%
Net Profit YoY
8.8%
94.7%
EPS (diluted)
$2.10

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BMY
BMY
ORCL
ORCL
Q1 26
$11.5B
Q4 25
$12.5B
$16.1B
Q3 25
$12.2B
$14.9B
Q2 25
$12.3B
$15.9B
Q1 25
$11.2B
$14.1B
Q4 24
$12.3B
$14.1B
Q3 24
$11.9B
$13.3B
Q2 24
$12.2B
$14.3B
Net Profit
BMY
BMY
ORCL
ORCL
Q1 26
$2.7B
Q4 25
$1.1B
$6.1B
Q3 25
$2.2B
$2.9B
Q2 25
$1.3B
$3.4B
Q1 25
$2.5B
$2.9B
Q4 24
$72.0M
$3.2B
Q3 24
$1.2B
$2.9B
Q2 24
$1.7B
$3.1B
Gross Margin
BMY
BMY
ORCL
ORCL
Q1 26
Q4 25
67.2%
Q3 25
71.9%
Q2 25
72.5%
Q1 25
72.9%
Q4 24
61.0%
Q3 24
75.1%
Q2 24
73.2%
Operating Margin
BMY
BMY
ORCL
ORCL
Q1 26
Q4 25
11.8%
29.5%
Q3 25
25.5%
28.7%
Q2 25
14.5%
32.1%
Q1 25
26.5%
30.8%
Q4 24
1.4%
30.0%
Q3 24
14.1%
30.0%
Q2 24
10.5%
32.8%
Net Margin
BMY
BMY
ORCL
ORCL
Q1 26
23.3%
Q4 25
8.7%
38.2%
Q3 25
18.0%
19.6%
Q2 25
10.7%
21.5%
Q1 25
21.9%
20.8%
Q4 24
0.6%
22.4%
Q3 24
10.2%
22.0%
Q2 24
13.8%
22.0%
EPS (diluted)
BMY
BMY
ORCL
ORCL
Q1 26
Q4 25
$0.54
$2.10
Q3 25
$1.08
$1.01
Q2 25
$0.64
$1.19
Q1 25
$1.20
$1.02
Q4 24
$0.05
$1.10
Q3 24
$0.60
$1.03
Q2 24
$0.83
$1.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BMY
BMY
ORCL
ORCL
Cash + ST InvestmentsLiquidity on hand
$9.6B
$19.2B
Total DebtLower is stronger
$-42.2B
Stockholders' EquityBook value
$30.0B
Total Assets
$205.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BMY
BMY
ORCL
ORCL
Q1 26
$9.6B
Q4 25
$10.2B
$19.2B
Q3 25
$15.7B
$10.4B
Q2 25
$12.6B
$10.8B
Q1 25
$10.9B
$17.4B
Q4 24
$10.3B
$10.9B
Q3 24
$7.9B
$10.6B
Q2 24
$6.3B
$10.5B
Total Debt
BMY
BMY
ORCL
ORCL
Q1 26
$-42.2B
Q4 25
$44.8B
Q3 25
$48.7B
Q2 25
$48.9B
Q1 25
$49.5B
Q4 24
$49.4B
Q3 24
$49.5B
Q2 24
$52.0B
Stockholders' Equity
BMY
BMY
ORCL
ORCL
Q1 26
Q4 25
$18.5B
$30.0B
Q3 25
$18.6B
$24.2B
Q2 25
$17.4B
$20.5B
Q1 25
$17.4B
$16.7B
Q4 24
$16.3B
$13.7B
Q3 24
$17.1B
$10.8B
Q2 24
$17.0B
$8.7B
Total Assets
BMY
BMY
ORCL
ORCL
Q1 26
Q4 25
$90.0B
$205.0B
Q3 25
$96.9B
$180.4B
Q2 25
$94.7B
$168.4B
Q1 25
$92.4B
$161.4B
Q4 24
$92.6B
$148.5B
Q3 24
$93.7B
$144.2B
Q2 24
$94.6B
$141.0B
Debt / Equity
BMY
BMY
ORCL
ORCL
Q1 26
Q4 25
2.43×
Q3 25
2.63×
Q2 25
2.81×
Q1 25
2.85×
Q4 24
3.03×
Q3 24
2.89×
Q2 24
3.05×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BMY
BMY
ORCL
ORCL
Operating Cash FlowLast quarter
$2.1B
Free Cash FlowOCF − Capex
$-10.0B
FCF MarginFCF / Revenue
-62.1%
Capex IntensityCapex / Revenue
74.9%
Cash ConversionOCF / Net Profit
0.34×
TTM Free Cash FlowTrailing 4 quarters
$-13.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BMY
BMY
ORCL
ORCL
Q1 26
Q4 25
$2.0B
$2.1B
Q3 25
$6.3B
$8.1B
Q2 25
$3.9B
$6.2B
Q1 25
$2.0B
$5.9B
Q4 24
$4.4B
$1.3B
Q3 24
$5.6B
$7.4B
Q2 24
$2.3B
$6.1B
Free Cash Flow
BMY
BMY
ORCL
ORCL
Q1 26
Q4 25
$1.6B
$-10.0B
Q3 25
$6.0B
$-362.0M
Q2 25
$3.6B
$-2.9B
Q1 25
$1.7B
$71.0M
Q4 24
$4.1B
$-2.7B
Q3 24
$5.3B
$5.1B
Q2 24
$2.1B
$3.3B
FCF Margin
BMY
BMY
ORCL
ORCL
Q1 26
Q4 25
12.8%
-62.1%
Q3 25
49.0%
-2.4%
Q2 25
29.0%
-18.4%
Q1 25
15.1%
0.5%
Q4 24
32.9%
-19.0%
Q3 24
44.3%
38.5%
Q2 24
16.9%
23.0%
Capex Intensity
BMY
BMY
ORCL
ORCL
Q1 26
Q4 25
3.0%
74.9%
Q3 25
2.6%
57.0%
Q2 25
2.9%
57.1%
Q1 25
2.3%
41.5%
Q4 24
3.1%
28.2%
Q3 24
2.7%
17.3%
Q2 24
2.1%
19.6%
Cash Conversion
BMY
BMY
ORCL
ORCL
Q1 26
Q4 25
1.82×
0.34×
Q3 25
2.87×
2.78×
Q2 25
2.99×
1.80×
Q1 25
0.80×
2.02×
Q4 24
61.65×
0.41×
Q3 24
4.62×
2.54×
Q2 24
1.38×
1.93×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BMY
BMY

Segment breakdown not available.

ORCL
ORCL

Software Support$4.9B31%
Cloud Infrastructure$4.1B25%
Cloud Applications$3.9B24%
Services Business$1.4B9%
Software License$939.0M6%
Hardware Business$776.0M5%

Related Comparisons